rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Altimmune, Inc.

ALT · Nasdaq

Health CareBiotechnologyNot moving yetGLP-1

ALT stood above a rising 150-day average in 2 of the last 52 weekly readings, and has been out of that trend for the last 33 weeks. It is 26.9% below that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 33
Industry in uptrend
15% -17 in 4 wk
Insider buys, 12 months
$635K
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
205 (+41)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 2 of 52 weeks.

17 Apr – 16 Oct
16%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
$0$212KNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months11
Sale orders, 12 months0
Buyers · sellers6 · 0
WhoDidSharesTraded
Jerome Benedict DursoPresident and CEObought15,000at $2.9513 Aug 2026filed 13 Aug 2026
John GillDirectorbought9,200at $3.416 Apr 2026filed 6 Apr 2026
Gregory L. WeaverChief Financial Officerbought10,000at $3.151 Apr 2026filed 1 Apr 2026
Jerome Benedict DursoPresident and CEObought15,000at $3.141 Apr 2026filed 1 Apr 2026
Gregory L. WeaverChief Financial Officerbought5,000at $3.546 Mar 2026filed 9 Mar 2026
Jerome Benedict DursoPresident and CEObought20,000at $3.546 Mar 2026filed 9 Mar 2026
Wayne PisanoDirectorbought5,000at $4.088 Jan 2026filed 9 Jan 2026
Catherine A. SohnDirectorbought500at $4.245 Jan 2026filed 5 Jan 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders205+41 on the quarter
New · exited59 · 19
Reported value$456.4M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
BlackRock, Inc.added · filed 7 Aug 202620,385,284$62.0M+7,590,007+59.3%
Deep Track Capital, LPnew · filed 14 Aug 202619,250,000$58.5M+19,250,000
STATE STREET CORPadded · filed 7 Aug 202612,098,540$36.8M+4,952,990+69.3%
TCG Crossover Management, LLCnew · filed 14 Aug 202610,000,000$30.4M+10,000,000
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 20268,177,752$24.9M+2,519,703+44.5%
VANGUARD PORTFOLIO MANAGEMENT LLCadded · filed 13 Aug 20267,330,265$22.3M+1,948,263+36.2%
MARSHALL WACE, LLPadded · filed 13 Aug 20266,841,055$20.8M+2,823,154+70.3%
VIKING GLOBAL INVESTORS LPnew · filed 14 Aug 20266,700,000$20.4M+6,700,000
RA CAPITAL MANAGEMENT, L.P.new · filed 14 Aug 20266,500,000$19.8M+6,500,000
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 20265,011,314$15.2M+1,904,218+61.3%
31 Mar 2023 – 30 Jun 2026
103152201Mar 23Dec 23Dec 24Sep 25Jun 26

Everyone who traded it

Christophe Arbet-Engels Company insiderChief Medical Officer · last 1 Oct 20260 · 0
Gregory L. Weaver Company insiderChief Financial Officer · last 1 Oct 20263 · 0
Richard Thomas Menziuso Company insiderPrincipal Accounting Officer · last 1 Oct 20260 · 0
Linda M. Richardson Company insiderChief Commercial Officer · last 16 Sep 20260 · 0
Jerome Benedict Durso Company insiderPresident and CEO · last 13 Aug 20264 · 0
M. Scot Roberts Company insiderChief Scientific Officer · last 31 Jul 20261 · 4
Catherine A. Sohn Company insiderDirector · last 1 May 20262 · 0
Diane Jorkasky Company insiderDirector · last 1 May 20261 · 1
John Gill Company insiderDirector · last 1 May 20263 · 2
Klaus Schafer Company insiderDirector · last 1 May 20261 · 1
Mitchel Sayare Company insiderDirector · last 1 May 20262 · 0
Philip Hodges Company insiderDirector · last 1 May 20260 · 3

Same industry

MRNA ModernaLeading+147%
ENTX Entera BioLeading+37%
XNCR XencorLeading+30%

Distance from each stock’s own 150-day average.

Government contracts

Awards1
Total$100.5M
Latest1 Apr 2009

From its SEC filings

Return on capital employedFY 2025 · to 31 Dec 2025-35.7%
Debt to equityFY 2025 · to 31 Dec 20250.15×
Share count trendFY 2025 · to 27 Feb 202617.3%
Cash and equivalentsFY 2025 · to 31 Dec 2025$43.8M
Free cash flowFY 2025 · to 31 Dec 2025−$67.5M

Analyst forecasts

No analyst forecasts yet.